Cryo Cell International Inc

Name: Cryo Cell International Inc standardized financial statements, quarterly
Creator: Listed

CCELNYSECIK 862692HealthcareFiscal year ends Nov 30

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$7.8m, Q3 FY2026

Operating income$2.2m, Q3 FY2026

Net income$1.3m, Q3 FY2026

Cryo Cell International Inc, income statement, quarterly
Line item	Unit	Q4 FY20232023-11-30	Q1 FY20242024-02-29	Q2 FY20242024-05-31	Q3 FY20242024-08-31	Q4 FY20242024-11-30	Q1 FY20252025-02-28	Q2 FY20252025-05-31	Q3 FY20252025-08-31	Q4 FY20252025-11-30	Q1 FY20262026-02-28	Q2 FY20262026-05-31	Q3 FY20262026-08-31
Revenue	$m	7.9	7.9	8.0	8.1	8.0	8.0	7.9	7.8	7.8	7.7	7.8	7.8
Cost of revenue	$m	2.0	2.1	2.0	2.1	1.6	2.0	1.9	1.8	1.7	1.7	1.7	1.6
Research and development	$m	0.4	0.5	0.2	0.2	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Selling, general and administrative	$m	5.4	4.4	4.0	4.2	6.0	4.6	4.3	3.9	5.4	5.0	4.6	3.8
Operating income	$m	(16.2)	0.8	1.4	1.4	(0.1)	1.1	1.5	1.9	(4.0)	0.8	1.2	2.2
Interest expense	$m	(0.2)	0.3	0.3	0.5	0.7	0.5	0.6	0.5	0.5	0.5	0.4	0.4
Income tax	$m	(4.8)	0.2	0.8	0.3	1.0	0.3	0.2	0.4	(0.8)	0.0	0.3	0.6
Net income	$m	(11.2)	0.6	0.7	1.1	(1.9)	0.3	0.4	0.7	(3.8)	0.0	0.6	1.3
Diluted EPS	$ per share	not reported	0.07	0.08	0.13	not reported	0.03	0.04	0.09	not reported	0.01	0.07	0.16
Basic EPS	$ per share	not reported	0.07	0.08	0.13	not reported	0.03	0.04	0.09	not reported	0.01	0.07	0.16

Balance sheet

Cash and equivalents$1.4m, Q3 FY2026

Long-term debt$8.2m, Q3 FY2026

Shareholders' equity−$16.4m, Q3 FY2026

Cryo Cell International Inc, balance sheet, quarterly
Line item	Unit	FY20232023-11-30	Q1 FY20242024-02-29	Q2 FY20242024-05-31	Q3 FY20242024-08-31	FY20242024-11-30	Q1 FY20252025-02-28	Q2 FY20252025-05-31	Q3 FY20252025-08-31	FY20252025-11-30	Q1 FY20262026-02-28	Q2 FY20262026-05-31	Q3 FY20262026-08-31
Cash and equivalents	$m	0.4	0.2	0.5	0.2	0.6	0.2	0.1	0.3	0.3	0.2	0.5	1.4
Current assets	$m	9.5	9.5	10.2	10.7	12.6	12.5	13.1	11.7	11.8	11.1	11.3	13.2
Total assets	$m	64.7	61.7	62.6	62.9	64.7	64.4	64.4	63.2	61.7	60.9	60.7	62.3
Current liabilities	$m	20.9	19.4	19.4	17.4	21.6	21.7	21.8	18.5	19.8	17.8	15.9	15.3
Total liabilities	$m	72.3	72.0	73.3	72.5	77.9	79.0	80.0	78.0	80.3	79.3	78.5	78.7
Long-term debt	$m	8.6	8.6	8.5	8.5	8.5	8.5	8.4	8.4	8.4	8.3	8.3	8.2
Shareholders' equity	$m	(11.0)	(10.3)	(10.7)	(9.6)	(13.2)	(14.7)	(15.6)	(14.8)	(18.6)	(18.4)	(17.8)	(16.4)

Cash flow

Operating cash flow$1.1m, Q3 FY2026

Capital expenditure$101.9k, Q3 FY2026

Share repurchases$0, Q3 FY2026

Cryo Cell International Inc, cash flow, quarterly
Line item	Unit	Q4 FY20232023-11-30	Q1 FY20242024-02-29	Q2 FY20242024-05-31	Q3 FY20242024-08-31	Q4 FY20242024-11-30	Q1 FY20252025-02-28	Q2 FY20252025-05-31	Q3 FY20252025-08-31	Q4 FY20252025-11-30	Q1 FY20262026-02-28	Q2 FY20262026-05-31	Q3 FY20262026-08-31
Operating cash flow	$k	3,344	(357)	1,773	2,437	2,157	954	707	2,537	1,281	652	1,846	1,142
Capital expenditure	$k	1,715	458	1,752	186	8.3	62.1	62.4	38.8	67.2	67.1	32.7	102
Dividends paid	$k	not reported	0.0	0.0	0.0	2,021	2,021	1,211	0.0	0.0	0.0	0.0	0.0
Share repurchases	$k	0.0	170	1,237	16.4	0.0	0.0	88.6	80.9	0.0	not reported	not reported	0.0

Diluted shares (weighted)8.07m, Q3 FY2026

Cryo Cell International Inc, shares, quarterly
Line item	Unit	Q1 FY20232023-02-28	Q2 FY20232023-05-31	Q3 FY20232023-08-31	Q1 FY20242024-02-29	Q2 FY20242024-05-31	Q3 FY20242024-08-31	Q1 FY20252025-02-28	Q2 FY20252025-05-31	Q3 FY20252025-08-31	Q1 FY20262026-02-28	Q2 FY20262026-05-31	Q3 FY20262026-08-31
Diluted shares (weighted)	k shares	8,475	8,332	8,342	8,325	8,232	8,174	8,200	8,126	8,074	8,056	8,055	8,065

Shares outstanding: 8.06m at Oct 8, 2026, from the cover of the 10-Q filed Oct 9, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. Listed shows no prices and gives no investment advice.